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Abstract 
Background: An increasing volume of prostate biopsies and a world-wide shortage of uro-
pathologists puts a strain on pathology departments. Additionally, the high intra- and inter-
observer variability in grading can result in over- and undertreatment of prostate cancer. 
Artificial intelligence (AI) methods may alleviate these problems by assisting the pathologist 
to reduce workload and harmonize grading. 
 
Methods: We digitized 6,682 needle biopsies from 976 participants in the population based 
STHLM3 diagnostic study to train deep neural networks for assessing prostate biopsies. The 
networks were evaluated by predicting the presence, extent, and Gleason grade of 
malignant tissue for an independent test set comprising 1,631 biopsies from 245 men. We 
additionally evaluated grading performance on 87 biopsies individually graded by 23 
experienced urological pathologists from the International Society of Urological Pathology. 
We assessed discriminatory performance by receiver operating characteristics (ROC) and 
tumor extent predictions by correlating predicted millimeter cancer length against 
measurements by the reporting pathologist. We quantified the concordance between grades 
assigned by the AI and the expert urological pathologists using Cohen’s kappa. 
 
Results: The AI achieved an area under the ROC curve of 0.997 for distinguishing between 
benign and malignant biopsy cores, and 0.999 for distinguishing between men with or 
without prostate cancer. The correlation between millimeter cancer predicted by the AI and 
assigned by the reporting pathologist was 0.96. For assigning Gleason grades, the AI 
achieved an average pairwise kappa of 0.62. This was within the range of the corresponding 
values for the expert pathologists (0.60 to 0.73). 
 
Conclusions: The performance of the AI to detect and grade cancer in prostate needle 
biopsy samples was comparable to that of international experts in prostate pathology. AI has 
potential to reduce high intra-observer variability and to provide diagnostic expertise in 
regions where this is currently unavailable. 
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Introduction 
Histopathological evaluation of prostate biopsies is critical to the clinical management of men 
suspected of having prostate cancer. Despite this importance, the histopathological 
diagnosis of prostate cancer is associated with several challenges: 
  
● More than one million men undergo prostate biopsy in the United States annually.1 
With the standard biopsy procedure resulting in 10-12 needle cores per patient, this 
means that more than 10 million tissue samples need to be examined by 
pathologists. The increasing incidence of prostate cancer in an aging population 
means that the number of biopsies is likely to further increase. 
● It is recognized that there is a shortage of pathologists internationally. In China, there 
is only one pathologist per 130,000 population, while in many African countries the 
ratio is of the order of one per million.2,3 Western countries are facing similar 
problems, with an expected decline in the number of practicing pathologists due to 
retirement.4 
● Gleason grade is the most important prognostic factor for prostate cancer and is 
crucial for treatment decisions. Gleason grade is based on morphologic examination 
and is recognized to be notoriously subjective. This is reflected in high intra- and 
inter-pathologist variability in reported grades, as well as both under- and over-
diagnosis of prostate cancer.5,6  
 
A possible solution to these challenges is the application of artificial intelligence (AI) to 
prostate cancer histopathology. The development of an AI to identify benign biopsies with 
high accuracy would decrease the workload of pathologists and allow them to focus on 
difficult cases. Further, an accurate AI could assist the pathologist with the identification, 
localization and grading of prostate cancer among those biopsies not culled in the initial 
screening process, thus providing a safety net to protect against potential misclassification of 
biopsies. AI-assisted pathology assessment could harmonize grading and reduce inter-
observer variability, leading to more consistent and reliable diagnoses and better treatment 
decisions. 
 
Using high resolution scanning, tissue samples can be digitized to whole slide images (WSI) 
and utilized as input for the training of deep neural networks (DNN), an AI technique which 
has been successful in many fields, including medical imaging.7–10 Despite the many 
successes of AI, little work has been undertaken in prostate diagnostic histopathology.11–16 
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Attempts at grading prostate biopsies by DNNs have been limited to small datasets or 
subsets of Gleason patterns, and they have lacked analyses of the clinical implications of the 
introduction of AI-assisted prostate pathology.  
  
In this study, we aimed to develop an AI with clinically acceptable accuracy for prostate 
cancer detection, localization, and Gleason grading. To achieve this, we digitized 8,313 
samples from 1,222 men included in the prospective and population based STHLM3 
prostate cancer diagnostic study undertaken in 2012-2015.17,18 We evaluated the 
performance of the model on an independent test set and through a comparison with 87 
cases of prostate cancer graded by the International Society of Urological Pathology (ISUP) 
Imagebase panel consisting of 23 experienced uro-pathologists.19 
Methods 
Sample population and data collection 
Between 2012 and 2015, the prospective and population-based STHLM3 study evaluated a 
diagnostic model for prostate cancer in men aged between 50 and 69 years.17,18 Among the 
59,159 participants, 7,406 (12.5%) underwent systematic biopsy according to a standardized 
protocol consisting of 10 or 12 needle cores; with 12 cores being taken from prostates larger 
than 35 cm3 (Table 1). Urologists who participated in the study and the study pathologist 
were blinded to the clinical characteristics of the patients. A single pathologist (L.E.) graded 
all biopsy cores according to the ISUP grading classification (where Gleason scores 6, 
3+4=7, 4+3=7, 8, and 9-10 are reported as ISUP grade 1 to 5, also referred to as Gleason 
Grade Groups) and delineated cancerous areas using a marker pen.20,21  
 
The biopsy cores were formalin fixed and stained with hematoxylin and eosin. A selection of 
8,313 biopsies from 1,222 STHLM3 participants was digitized. The cases were chosen to 
represent the full range of diagnoses, with an over-representation of high-grade disease. We 
used images from 1,631 cores from a random selection of 246 (20%) men to evaluate the 
performance of the AI, while the rest were used for model training. That is, all biopsies from 
a given man were assigned to either the training or the test dataset.22 In addition, to further 
enrich the data, 152 slides from men with prostate cancers of the highest grades (ISUP 4 
and 5) were collected from Capio S:t Göran Hospital, Stockholm. These slides were re-
graded by L.E. and utilized for training purposes only. As an additional test set, we digitized 
87 cores from the Pathology Imagebase, a reference database launched by ISUP.19 Test 
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images, as well as all cores from Imagebase patients, were not part of model development 
and were excluded from any analysis until the final evaluation. For details concerning data 
collection, see Appendix. 
Artificial intelligence framework 
Image pre-processing 
We processed the WSIs with a segmentation algorithm based on Laplacian filtering to 
identify the regions corresponding to tissue sections and annotations drawn adjacent to the 
tissue (Figure S1). We then extracted digital pixel-wise annotations, indicating the locations 
of cancerous tissue of any grade, by identifying the tissue region corresponding to each 
annotation. To obtain training data representing the morphological characteristics of Gleason 
patterns 3, 4 and 5, we extracted numerous partially overlapping smaller images, or patches, 
from each WSI. Each patch was small enough to largely represent only benign or cancerous 
tissue. We used patch dimensions of 598 x 598 pixels (approx. 540 x 540 µm) at a resolution 
corresponding to 10X magnification (pixel size approx. 0.90 µm). The process resulted in 
approximately 5.1 million patches usable for training a DNN. See Appendix for details (Table 
S1). 
Deep neural network model for classification of image patches 
We used two DNN ensembles, each consisting of 30 Inception V3 models pre-trained on 
ImageNet, with classification layers adapted to our outcome.23,24 The first ensemble 
performed binary classification of image patches into benign or malignant, while the second 
ensemble classified patches into Gleason patterns 3 to 5. To reduce label noise in the latter 
case, we trained the ensemble on patches extracted from cores containing only one Gleason 
pattern (i.e. cores with Gleason score 3+3, 4+4, or 5+5). Importantly, the test data still 
contained cores of all grades to provide a real-world scenario for evaluation. Each DNN in 
the first and the second ensemble thus predicted the probability of each patch being 
malignant, and whether it represented Gleason pattern 3, 4, or 5, respectively. See Appendix 
for details (Figure S2). 
Boosted tree model for core-level estimation of cancer grade and length 
Once the probabilities for the Gleason pattern at each location of the biopsy core were 
obtained from the DNN ensembles, we mapped them to core-specific characteristics (ISUP 
grade and cancer length) using boosted trees.25 All cores in the training data were used for 
 6 
 
training the boosted trees. Specifically, aggregated features from the patch-wise probabilities 
predicted by each DNN for each core were used as input to the boosted trees, and the 
clinical assessment of ISUP score and cancer length were used as outcomes. See Appendix 
for details. 
Evaluation metrics 
Cancer detection 
We summarized the operating characteristics of the AI system in a Receiver Operating 
Characteristic (ROC) curve and the Area Under the ROC Curve (AUC). We then specified a 
range of acceptable sensitivities for potential clinical use, and evaluated achieved specificity 
(both on core-level and patient-level) when compared to the pathology report.  
Cancer length estimation 
We predicted cancer length in each core and compared it to the cancer length described in 
the pathology report. The comparison was undertaken on individual cores as well as on 
aggregated cores (i.e. total cancer length) for each man. Linear correlation was assessed on 
both all cores and men, as well as restricted to positive cores and men. In addition, the 
patch-wise predictions were mapped to their spatial locations on each biopsy core, thus 
permitting the generation of visualizations of the predictions. 
ISUP grading 
Cohen’s kappa with linear weights was used for evaluating the AI’s performance against 
pathologists on the Imagebase test set. Linear weights emphasize a higher level of 
disagreement of ratings further away from each other on the ordinal ISUP scale, in 
accordance with previous publications on the Imagebase study.19 Each of the 87 slides in 
Imagebase was graded by each of the 23 Imagebase panel pathologists, and additionally by 
the AI. To evaluate how well the AI agreed with the pathologists, we calculated all pair-wise 
kappas and summarized the average for each of the 23 raters. In addition, we estimated the 
kappa with a grouping of the Gleason scores in ISUP grades (grade groups) 1, 2-3 and 4-5. 
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Results 
Cancer detection 
We estimated the AUC representing the ability of the AI to distinguish malignant from benign 
cores to 0.997 (Figure 1). For predicting whether a man had cancer or not, the AUC was 
0.999. As an example (Figure 1; second row from top), at a sensitivity of 99.6%, the AI 
achieved a specificity of 86.6%. At this sensitivity level, the AI failed to detect three cores 
with cancer (two ISUP grade 1 and one ISUP grade 2, all with less than 0.5 mm cancer) 
across 721 malignant biopsy cores in the independent test data. No cancer was 
misdiagnosed since other malignant cores from the same men were correctly classified.  
Cancer length estimation 
A visualization of the estimated localization of malignant tissue for an example biopsy is 
presented in Figure 2. The correlation between the cancer length estimates of the AI and the 
measurements of the pathologist was 0.96 (0.93 for positive cores). When aggregating the 
cancer extent of all cores within a case, the correlation was 0.98, both for all men and for 
men positive for cancer (Figure 3). An online tool 
(https://tissuumaps.research.it.uu.se/sthlm3/) allows interactive examination of predictions 
generated for 30 cores randomly selected (5 per ISUP score and 5 benign) from the test set. 
ISUP grading 
The average pairwise kappa achieved by the AI relative to the panel of pathologists on the 
87 Imagebase cases was 0.62. The pathologists had values ranging from 0.60 to 0.73, with 
the study pathologist (L.E.) having a kappa of 0.73. When considering a narrower grouping 
of ISUP grades (ISUP 1, ISUP 2-3 and ISUP 4-5), which often forms the basis for primary 
treatment selection, the AI scored even higher relative to the pathologists (Figure 4). The 
grades assigned by the panel and the AI to each Imagebase case are shown in Appendix 
(Figure S3). 
 
The kappa obtained by the AI relative to the pathology report in the independent test set of 
1,631 cores was 0.83 for all cores and 0.70 for positive cores only (see Appendix, Figure 
S4). 
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Discussion 
Grading prostate cancer can be a difficult procedure due to the complex nature of the score 
and its derivation. This has also been true for computer algorithms aiming at automating 
grading. The challenge is not only to develop an AI for this task, but also to demonstrate that 
it is consistent with current state-of-the-art diagnosis of prostate histopathology. Here, we 
have for the first time demonstrated AI-based grading of prostate biopsies on the level of 
leading urological pathologists represented by the ISUP Imagebase panel. 
 
Due to the poor discriminative ability of the prostate specific antigen test and the systematic 
biopsy protocol of 10-12 needle cores, which is still in common usage, most biopsies 
encountered in clinical practice are of benign tissue. To reduce the workload of assessing 
these samples, we evaluated the AI’s ability to assist the pathologist by pre-screening 
benign from malignant cores. With an estimated AUC of 0.997, the system could 
automatically remove 809 benign biopsies from 246 men without missing a single man out of 
the 211 with cancer diagnosed by the study pathologist (Figure 1). Since the pathology 
report was used as gold standard for this evaluation, the AI, by design, cannot achieve a 
higher sensitivity than the reporting pathologist. However, some malignant cores may still be 
overlooked by the pathologist but detected by the AI. As an illustration of this, Ozkan et al. 
evaluated the agreement of two pathologists in the assessment of cancer in biopsy cores.5 
Following examination of 407 cases, one pathologist found cancer in 231 cases, while the 
other found cancer in 202 cases. This suggests that an AI can not only streamline the 
workflow but could also improve sensitivity by detecting cancer foci that would otherwise be 
accidentally overlooked.  
 
In this study, we have also evaluated the assessment of tumor burden (cancer length). We 
believe that both cancer detection and cancer length measurements can now be automated 
without sacrificing patient safety. In support of this and to provide interpretations of the 
DNN’s predictions, we have published on our website high-resolution images of 30 cores 
randomly selected from the test data, accompanied by their ISUP grades and the AI’s 
predictions. 
 
The first attempt to use DNNs for the detection of cancer on prostate biopsies was reported 
by Litjens et al.15 Using an approach similar to ours but based on a small dataset, they could 
safely exclude 32% of benign cores. A more recent study by Campanella et al. demonstrated 
an AUC of 0.977 for cancer detection.16 There have also been attempts to undertake grading 
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of prostate tissue derived from prostatectomy or based on tissue microarrays.14,26 None of 
these studies achieved expert uro-pathologist level consistency in Gleason grading, 
estimated tumor burden or investigated the reproducibility of grading on needle biopsies, 
which are utilized for diagnostics in virtually every pathology laboratory worldwide. Moreover, 
no previous study has used a well-defined cohort of samples to estimate the clinical 
implications, with respect to key medical operating characteristic metrics such as sensitivity 
and specificity.27  
 
The strengths of our study include the use of well-controlled, prospectively collected and 
population-based data covering a large random sample of men with both the urologists and 
the pathologist blinded to patient characteristics. Prostate cancers diagnosed in STHLM3 are 
representative for a screening-by-invitation setting, and the data include cancer variants that 
are notoriously difficult to diagnose (pseudohyperplastic and atrophic carcinoma), slides 
which required immunohistochemistry, and mimickers of cancer (Table S6). Despite these 
difficult cases, the AI achieved near perfect diagnostic concordance with the study 
pathologist. The study was subjected to a strict protocol, where the splitting of cases into 
training and test sets was performed at a patient level and all analyses were pre-specified 
prior to the evaluation of the independent test set, including code for producing tables, 
figures, and result statistics. A further strength is the use of Imagebase which is a unique 
dataset for testing the performance of the AI against highly experienced urological 
pathologists. 
 
We trained the AI using annotations from a single, highly experienced urological pathologist 
(L.E.). The decision to rely on a single pathologist for model training was done to avoid 
presenting the AI with conflicting labels for the same morphological patterns and to thereby 
achieve more consistent predictions. L.E. has in several studies demonstrated high 
concordance with other experienced uro-pathologists, and therefore represents a good 
reference for model training.28,29 For model evaluation, however, it is critical to assess 
performance against multiple pathologists (Figure 3). 
 
The main limitation of this study is the lack of exact pixel-wise annotations, since the 
annotations may highlight regions that include a mixture of benign and malignant glands of 
different grades. To address this issue, we used a patch size large enough to cover 
glandular structures but small enough to minimize the presence of mixed grades within a 
patch, and we focused our attention on core and patient level performance metrics, which 
avoids caveats of patch-level evaluation and is clinically more meaningful.  
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Conclusions 
We have demonstrated that an AI based on DNNs can reach the level of highly experienced 
urological pathologists for the grading of prostate biopsies. We believe that the use of this 
system can increase sensitivity and promote patient safety by providing decision-support 
and by focusing the attention of the pathologist on regions of interest. In addition, the use of 
this system can reduce high intra-observer variability in the reporting of prostate 
histopathology by producing reproducible and consistent grading. A further benefit is that AI 
can provide diagnostic expertise in regions where this is currently unavailable. Our results 
warrant international validation, which we are pursuing in an ongoing project where we 
collect slides from seven countries. 
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Table 1: Subject characteristics among all biopsied men in STHLM3 and among men whose biopsies 
were digitized, tabulated by men (top) and by individual biopsy cores (bottom). No cancer grade 
information is shown for Imagebase, as the grading of this set of samples was performed 
independently by multiple observers. Imagebase cancer length was assessed by L.E. 
 15 
 
Figure 1: ROC and AUC for cancer detection (left); by individual cores and by men. Four operating 
points on the core level curve are highlighted (right). The first two columns from left show the number 
of biopsy cores that could be discarded from further consideration and the number of biopsy cores 
that would need pathological evaluation, respectively. The values in parentheses indicate the 
corresponding specificity and sensitivity. The next five columns show the number and percentage of 
missed malignant cores by ISUP score for each operating point. The rightmost column indicates the 
number and percentage of missed cancers among all men with cancer. 
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Figure 2: Color-coded visualization of cancer grades estimated by the AI. The colors represent the 
estimated probabilities for the presence of benign (blue), malignant low grade (Gleason 3, yellow) and 
malignant high grade (Gleason 4 or 5, red) tissue at different locations of the biopsy (left). A 
magnified view of the AI output (center) and the corresponding H&E stained tissue (right) are shown 
for a region where an estimated transition between low- and high-grade morphology can be observed. 
This core from the test data was graded as ISUP 3 (GS 4+3) by the study pathologist. 
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Figure 3: Scatterplots presenting the concordance between cancer lengths estimated by the AI and 
the pathologist for independent test data. Results are shown for individual cores (left) and aggregated 
over cores for each man (right). Corresponding linear correlation coefficients computed for all cores 
and malignant cores only are shown in each plot. Data points in the left plot are jittered along the x-
axis for clarity. 
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Figure 4: Cohen’s kappa for each pathologist ranked from lowest to the highest. Each kappa value is 
the average pair-wise kappa for each of the pathologists compared against the others. To account for 
the natural order of the ISUP scores we used linear weights. The AI is highlighted with a black dot and 
an arrow. The study pathologist (L.E.) is highlighted with an arrow. Values computed based on all five 
ISUP scores are plotted in red, while values based on a grouping of ISUP scores commonly used for 
treatment decision are shown in blue. 
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Appendix 
1. Sample collection 
Sample collection was carried out in two rounds. The first selection was the first 500 men 
with prostate cancer who were diagnosed in the Stockholm-3 study. All 10-12 cores from 
these men were scanned, in total 5,662 slides. The second round included all men with at 
least one core graded as Gleason Score (GS) 4+4 or 5+5 to enrich the amount of training 
examples from high grade biopsies. It also included a random selection of 497 men with at 
least one biopsy graded as GS 3+3. From each of these men, we included all positive cores 
and a randomly selected negative core. Finally, we randomly selected 139 cancer-free men 
from whom we included one randomly selected core. Table 1 shows the distribution of 
grades among the selected men. 
 
Due to the relatively few biopsy cores with GS 5+5 in the Stockholm-3 study, we collected an 
additional set of 271 slides from 93 men with high grade disease. Out of these slides, 23 
were graded by Lars Egevad at Karolinska Hospital. The remaining 248 slides were 
collected in the Capio S:t Göran Hospital (Stockholm) between 2016-2017, and re-graded by 
Lars Egevad for the purpose of the AI development presented here. As these samples are 
not part of the Stockholm-3 cohort, we did not include them in the evaluation (i.e. in the 
independent test set), but only used them in training to improve the AI system’s 
discrimination for high grade disease. 
 
The linear cancer extent was generally measured from end to end in cases with 
discontinuous cancer. However, in cases with 1 or 2 cores infiltrated by low grade 
discontinuous cancer with a benign gap exceeding 3 mm, benign tissue was subtracted in 
the reporting of total cancer extent. 
2. Image acquisition 
The first round of slides was digitized using a Hamamatsu C9600-12 scanner and NDP.scan 
software v. 2.5.86 (Hamamatsu Photonics, Hamamatsu, Japan). The following batches of 
slides were scanned using an Aperio ScanScope AT2 scanner and Aperio Image Library v. 
12.0.15 software (Leica Biosystems, Wetzlar, Germany). The pixel size at full-resolution 
 20 
 
(20X) was 0.45202 µm (Hamamatsu) or 0.5032 µm (Aperio). The resulting RGB images 
were stored at 8 bits per channel in NDPI (Hamamatsu) or SVS (Aperio) format. 
3. Hardware and software 
Computations were performed on two graphics processing unit (GPU) clusters (Tampere 
Center for Scientific Computing, Finland and CSC IT Center for Science, Finland), utilizing a 
total of 136 x Tesla P100 GPUs (Nvidia, Santa Clara, CA, USA), distributed on 37 nodes. 
The GPUs were running Nvidia driver v. 410.79, CUDA v. 9.2.148 and cuDNN v. 7.3.1. The 
nodes were equipped with either a 20-core Xeon E5-2640 v4 or a 24-core Xeon E5-2680 v4 
CPU (Intel, Santa Clara, CA, USA), 256 or 512 GB RAM and 1.2 or 1.6 TB of local SSD 
storage. We used 32-bit floating point precision for GPU computation. 
 
Images were accessed using OpenSlide1 (v. 3.4.1) via the Python interface (v. 1.1.1) and an 
interface2 for MATLAB (The MathWorks, Natick, MA, USA). Pre-processing steps for image 
segmentation and label digitization were performed using MATLAB R2017b. Deep neural 
networks (DNN) were implemented in Python 3.6.4 using Keras3 (v. 2.2.4) with the 
TensorFlow4 (v. 1.11.0) backend, and all boosted trees using the Python interface for 
XGBoost (v. 0.72). 
4. Image pre-processing 
4.1. Segmentation of tissue 
Our image pre-processing workflow is depicted in Figure S1. First, we employed a Laplacian 
filtering algorithm to separate tissue from background and pen mark annotations. We first 
read images downsampled by a factor of 16 directly from the resolution pyramids present in 
the image files using Openslide1. We then converted the images from RGB to grayscale in 
accordance with the NTSC standard by calculating the weighted sum 0.2989 x R + 0.5870 x 
G + 0.1140 x B for each pixel. A filter approximating the 2D Laplacian operator, implemented 
in MATLAB’s fspecial function, was applied on the image and the absolute magnitude of the 
resulting response was thresholded using Otsu’s method5. This results in a binary mask 
indicating the locations of regions with variation in pixel intensity, mainly corresponding to in-
focus tissue. The regions were smoothed by applying morphological closing with a disk-
shaped structuring element having a radius of 50 µm, followed by filling of holes and removal 
of objects having an area smaller than 100 000 µm2. Any remaining pen marks were 
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removed based on their color by performing the HSV transform and excluding any objects 
whose mean hue was less than 0.7.  
 
The final binary tissue masks T were rescaled back to full resolution using nearest neighbor 
interpolation, followed by lossless PackBits compression, and storage in Tiff or BigTiff format 
(depending on image dimensions) using a tile size of 1024 and ‘Chunky’ planar 
configuration. 
4.2. Segmentation of pen marks 
To segment the penmark annotations, downsampled images were first read and converted 
to grayscale as described above for the tissue segmentation. Dark regions were extracted by 
applying Otsu’s thresholding5, followed by taking the complement of the resulting binary 
mask and applying morphological closing with a disk-shaped structuring element having a 
radius of 50 µm. Candidate pen mark regions were obtained via a pixel-wise logical 
operation as the set of pixels belonging to the dark regions but not belonging to the tissue 
regions. The regions were further refined by filling of holes and removal of objects having an 
area smaller than 100 000 µm2 or width less than 400 µm. The minimal width criterion is 
needed to remove the long but thin slide edges visible in some WSIs. Any remaining out-of-
focus tissue regions falsely detected as pen marks were removed based on their color by 
performing the HSV transform and excluding any objects, whose mean hue exceeded 0.6. 
 
The final binary pen masks P were rescaled back to full resolution using nearest neighbor 
interpolation, followed by lossless PackBits compression, and storage in Tiff or BigTiff format 
(depending on image dimensions) using a tile size of 1024 and ‘Chunky’ planar 
configuration. 
4.3. Digitization of annotations 
Relying on the tissue masks T and pen masks P, we generated digital pixel-wise label 
masks L, indicating whether each pixel represents background, normal tissue or cancer 
tissue. For this purpose, the tissue and pen masks were utilized at a resolution 
corresponding to downsampling by a factor of 16 relative to full resolution. A smoothed 
version of the tissue mask Ts was generated by applying morphological closing with a disk-
shaped structuring element having a radius of 100 µm, followed by filling of holes. 
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In order to populate a binary mask C indicating tissue pixels labeled as cancerous, each pen 
mark region Pi in pen mask P was processed according to the following algorithm: 
1. Smooth Pi by morphological closing with a disk-shaped structuring element (radius 
100 µm) and fill holes. 
2. Set any overlapping tissue and pen mark pixels Ts ∩ Pi to FALSE in both masks. 
3. Find the set of pixels at tissue boundaries TB. 
4. Find the set of pixels at the boundaries of this pen mark PB. 
5. For each pixel in PB, find nearest pixel in TB via Kd-tree search
6 to construct the set 
of nearest tissue pixels TN. 
6. Discard all pixel pairs in PB and TN located further than 2000 µm from each other. 
7. Compute the mean direction θ and circular variance σ of the vectors defined by 
starting points in PB and end points in TN
7. 
8. Discard all pixel pairs j in PB and TN where the direction of the vector TN,j - PB,j differs 
from θ by more than θ t, where θ t is an angle of 20° or πσ radians, whichever is 
larger. If no pairs satisfy the criterion, keep the two pairs with direction closest to θ. 
9. For each pixel j in TN, attempt to locate the pixel on the opposite side of the tissue 
section by starting from TN,j and proceeding in the direction defined by the vector TN,j 
- PB,j until the first non-tissue pixel is encountered or the distance from PB,j exceeds 
2000 µm. Collect the located pixels into the set TO. 
10. Get the convex hull of the set of points TN ∪ TO as a binary image H and thicken it by 
3 pixels to rectify interpolation errors. 
11. Assign the set of pixels H ∩ T a value of TRUE in C. 
 
Based on the mask C, annotated tissue pixels were assigned the label 2 (i.e. cancer) in the 
label mask L. Non-annotated tissue pixels located on the same tissue sections as annotated 
tissue were assigned the label 1 (i.e. normal). Non-tissue regions and tissue regions not 
containing any annotated tissue were assigned the label 0 (i.e. background/unknown). The 
slides in our dataset typically contain two tissue sections, only one of which is annotated with 
pen marks by a pathologist, and we therefore chose to disregard the unannotated section to 
reduce label uncertainty.  
 
To avoid regions with locally inconsistent labels, we refined the initial label mask L by first 
applying morphological dilation with a disk-shaped structuring element (radius 100 µm) to 
the regions labeled as cancer, and then applied the same operation to the regions labeled as 
normal tissue. Finally, we introduced some margin at the boundaries of cancerous tissue by 
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dilating the regions labeled as cancer with a disk-shaped structuring element (radius 700 
µm) and assigning the label 0 (i.e. unknown) to all tissue pixels within the expanded region. 
 
For slides containing only benign tissue and hence no pen marks, we directly assigned the 
label 1 to all tissue pixels indicated by T instead of applying the algorithm described above. 
 
For a subset of 62 slides with grade-specific annotations relying on color-coded pen marks, 
we used a modified version of the above algorithm. For each pen mark region Pi on these 
slides, we computed the mean RGB value of the region from the original image. We then 
computed the Euclidean distance between this RGB vector and each of the possible colors: 
green (0, 255, 0) for Gleason 3, blue (0, 0, 255) for Gleason 4 and black (0, 0, 0) for Gleason 
5. The color producing the shortest distance was used as the basis of labeling the 
corresponding tissue region. That is, instead of assigning annotated tissue pixels the label 2 
(i.e. cancer) in the label mask L, we assigned the values 3 (Gleason 3), 4 (Gleason 4) or 5 
(Gleason 5). Pixels with conflicting labels indicated by multiple, differently colored pen marks 
were assigned the label 255 (mixed Gleason). 
 
The final unsigned 8-bit integer label masks L were rescaled back to full resolution using 
nearest neighbor interpolation, followed by lossless LZW compression, and storage in Tiff or 
BigTiff format (depending on image dimensions) using a tile size of 1024 and ‘Chunky’ 
planar configuration. 
4.4. Extracting patches from the WSI 
To extract image regions, which are small enough to mainly represent only one class of 
tissue and to fit in GPU memory, we divided each WSI into smaller, partially overlapping 
patches. Several preprocessing operations were simultaneously performed: exclusion of 
non-tissue regions, assignment of class labels for each patch, and adjustment of pixel size. 
We used the pre-generated tissue masks T, pen masks P and label masks L as the basis of 
this process. The masks were downsampled by a factor of 16 via nearest-neighbor 
interpolation to speed up processing while retaining their original level of fidelity. Patch 
extraction was run in parallel on multiple CPU cores. 
 
Each WSI was processed following a sliding-window approach with tunable stride s, patch 
size t and resolution level r. The resolution level corresponds to a downsampling factor of 2r 
relative to full resolution and an optical magnification of 20/2r. We used s = 299 px (approx. 
135 µm), r = 1 (pixel size approx. 0.90 µm) and experimented with different values for t 
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ranging from 598 px (approx. 270 µm) to 1196 px (approx. 540 µm). For each window, we 
first extracted the corresponding region from T. If less than 50% of the pixels within the 
region were indicated to be tissue, we skipped to the next window. Otherwise, we extracted 
the same region from L and assigned the patch a label according to the mode of tissue pixel 
labels in the label mask. We observed improving classification performance with increasing 
patch size, up until 1196 px (540 µm), which was the largest size feasible in terms of 
available GPU memory (data not shown). 
 
We then read the image data of the patch at the specified location and resolution level 
directly from the resolution pyramids present in the image files using Openslide1. If the 
desired level r was not present in the image file, we read the image at the next available 
higher resolution level. The patch was then resized to its final dimensions, at the specified 
resolution level, via Lanczos interpolation. At this point we also compensated for the different 
pixel size of the Hamamatsu and Aperio scanners by upsampling patches from Aperio slides 
to match the higher resolution of Hamamatsu. As a result, all produced patches had the 
same pixel size and pixel dimensions, each covering a physical region of identical size in 
micrometers. Any pixels in the patch indicated as non-tissue in T or as pen marks in P were 
then assigned a constant value corresponding to fully white (255, 255, 255) to remove any 
background patterns and annotation information from the image data. Finally, the patches 
were compressed using JPEG compression (quality 80) and stored on disk, either as .jpg 
files (one file per patch) or as .tar archives (one file per slide), depending on disk hardware 
used in downstream steps. 
5. Data management and quality control 
Prior to image preprocessing, all WSIs were visually examined to exclude slides unsuitable 
for analysis. The excluded slides included 86 slides representing immunohistochemical 
instead of H&E staining, 8 slides with failed H&E staining resulting in near complete lack of 
stain, 3 slides with corrupted data, and 23 slides containing smeared pen marks spread on 
top of tissue regions. 
 
All tissue, pen and label masks were visually examined to verify that the segmentation and 
digital annotations were accurate. Masks with inaccuracies were refined manually using a 
purpose-built interactive tool in MATLAB. For a total of 10,016 processed slides, 81 tissue 
masks (0.8%), 109 pen masks (1.1%) and 142 label masks (1.4%) required manual 
corrections. The corrections were mainly due to debris falsely detected as tissue, faint pen 
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marks missed by the algorithm, and slide labels or other text located close to slide edges 
falsely detected as pen mark annotations. The presence or absence of pen marks, indicative 
of cancerous or benign slides, respectively, was confirmed visually and checked for 
consistency with the clinical data. 
 
A total of 10,185 cores were digitized during multiple rounds of scanning (Table S1). We 
developed a database for organizing the images together with clinical information. The 
filenames of the scanned slides contain the study specific identification variable that is used 
to link the images to the clinical data. A total of 268 (2.6%) images from scanning had 
corrupted filenames, which made linkage to clinical data impossible. There was an overlap of 
slides that were rescanned between rounds of scanning, and in these cases we kept the 
slides from the first scanning round and excluded 613 rescanned slides. Furthermore, we 
excluded 45 slides that were duplicated within the same scanning round and 298 slides 
where there was an inconsistency between the cancer pen mark on the image and the 
cancer indicator variable in the clinical data. 
6. Patch-level classifier 
6.1. Model 
We used a two-stage model for classifying individual image patches (see Figure S2). The 
first stage of the model classifies image patches in binary fashion as either benign or 
cancerous, while the second stage performs Gleason grading. We included the benign class 
also into the second stage model in order to obtain a richer representation of the data, and to 
allow optionally applying or evaluating the two model stages separately of each other. The 
utility of the two-stage approach is three-fold: 1) it allowed us to fully utilize all training data, 
2) it allowed uncoupling the training of models for the detection and grading tasks, which 
require different numbers of training epochs to avoid overfitting, and 3) it enables adjusting 
the classifier’s operating point for the cancer detection task in a straightforward manner, 
independently of the Gleason grading task (see Section 6.2. for details). 
 
We evaluated the following convolutional neural network (CNN) architectures: Inception V38, 
ResNet509 Inception-ResNet V210 and Xception11. Based on evaluation on validation data (a 
temporary split of the training data to enable independent evaluation of different models’ 
performance without testing on the independent test set), Inception V3 offered the best 
performance in terms of classification accuracy (see Section 8.1; Table S2). In all cases, we 
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applied global average pooling to the output of the last convolutional layer, followed by a 
dense layer with softmax activation to output a vector of estimated probabilities over all 
classes. The input shape was matched to the patch size (typically 598 x 598 pixels). 
 
To improve generalization, we used an ensemble of multiple CNN models at each of the two 
stages. All these CNNs share the same architecture, and variability within the ensembles 
arises from the stochastic sampling during training. We used ensembles of 5 CNNs for cross 
validation experiments on training data and observed improved performance compared to 
using a single CNN (see Section 8.2.; Table S3). When training the final ensembles on all 
training data, we used 30 CNNs for each of the two stages. 
6.2. Training 
For training the binary first stage models, we used all benign and cancer patches from all 
training slides, irrespective of Gleason grade. For training the second stage models, we used 
a four class setting: benign, and Gleason patterns 3, 4 and 5. We used benign patches from 
all training slides, and inferred the Gleason grade label of each cancerous patch from the 
corresponding clinical data. Due to the lack of annotations indicating where each Gleason 
pattern is located on slides with multiple patterns (e.g. 3+4), we only used cancerous 
patches from slides with a single Gleason pattern (e.g. 3+3) for training. As an exception to 
this rule, we assigned patch-level Gleason labels directly based on grade-specific 
annotations where available (62 slides). In these cases, the maximum of the slide-level 
Gleason grades was assigned to patches with a mixed Gleason label. At both stages, we 
excluded patches with the label ‘unknown’ from training. 
 
As an alternative to discarding slides with multiple Gleason patterns when training the 
second stage model, we evaluated an iterative approach. This involved: 1) training a model 
only on slides featuring a single Gleason pattern, 2) applying this model to predict the patch-
level Gleason grades for slides featuring multiple patterns and 3) either fine-tuning the model 
further or training a new model from scratch using the predicted grades as additional training 
labels. Moreover, we experimented with using the primary Gleason grade (e.g. 3 for a 3+4 
slide) as the label for all patches from a slide, or randomly choosing the Gleason grade for 
each patch from the two slide-level grades. Our experiments indicated that none of these 
approaches improved classification performance compared to only using single Gleason 
slides as training data (data not shown). 
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In order to compensate for the considerably imbalanced distribution of different classes in 
the training data, which can be detrimental for CNN models12, we performed class balancing 
via subsampling before each ‘epoch’. Specifically, we always included all training patches 
representing the rarest class, and randomly sampled the same amount of patches from all 
other classes. This results in a uniform class distribution without duplicated examples. The 
model was then trained until this set of patches was exhausted, and the random sampling 
step was repeated with replacement for the next ‘epoch’. In our terminology, an epoch thus 
refers to a full pass through the minority class training examples. We trained the first stage 
models for 15 epochs and the second stage models for 60 epochs (see Section 8.3.; Table 
S4-S5). 
 
To improve generalization and to obtain rotational invariance, each patch was randomly 
rotated by either 0°, 90°, 180° or 270°, and then flipped vertically with a probability of 50% 
before being fed to the CNN. This data augmentation step was repeated every time a patch 
was drawn. As a result of this approach, each patch was presented to the CNN in different, 
randomly sampled orientations at different epochs, without increasing the overall number of 
patches processed during a single epoch. 
 
For optimization, we employed the Adam13 algorithm using the following default parameters: 
learning rate = 0.001, β1 = 0.9, β2 = 0.999, ε = 10
-7, decay = 0 and categorical cross entropy 
as the loss function. We evaluated initialization with random weights or weights trained on 
ImageNet14, and opted for the latter due to faster convergence. We used a minibatch size of 
32 for Inception V3, and 16 for all other architectures, as dictated by the amount of available 
GPU memory. 
 
During training, we employed multiple GPUs following the data parallelism strategy 
implemented in Keras. More specifically, the model was replicated on each GPU, each 
minibatch was divided into multiple sub-batches, and each one of them was processed by 
one GPU. The results were then concatenated on the CPU and the CNN weights were 
synchronously updated for all model replicas. We typically used two parallel GPUs per 
training run. Model training took approximately 5 or 3 days per one first stage or second 
stage CNN, respectively. 
6.3. Prediction 
In the prediction phase, we applied each trained model to all patches from slides 
representing the test set. No test-time data augmentation was used. This resulted in a set of 
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predicted class-wise probabilities output by each model for each patch. These probabilities 
were further used as input for slide-level classification (see Section 7). 
6.4. Visualization 
For the purpose of visualization in the online viewer (accessible at 
https://tissuumaps.research.it.uu.se/sthlm3), we first computed the mean of the predicted 
probabilities over all the models in the ensemble for each patch, resulting in a single vector 
of class-wise probabilities per patch. Due to partial overlap between the patches, each pixel 
in the WSI is covered by multiple patches. Therefore, for each pixel, we computed the mean 
probabilities over all patches associated with the pixel, resulting in a single vector of class-
wise probabilities per pixel. Bilinear interpolation was used to scale up the array of 
probabilities to match the dimensions of the full-resolution WSI. 
 
To represent and store the data as an RGB image, hereafter referred to as a confidence 
mask, we constructed the channels as follows:  
1. Cancer of any grade: The complement of the probability of the benign class predicted 
by the first stage ensemble. 
2. Low grade cancer: The probability of Gleason grade 3 predicted by the second stage 
ensemble. 
3. High grade cancer: The sum of the probabilities of Gleason grade 4 and 5 predicted 
by the second stage ensemble. 
 
The values were converted from floating point to uint8 precision and the confidence mask 
was stored in TIFF format using LZW compression. The confidence mask was then tiled into 
pyramidal DZI format using vips15 with a tile size of 512, overlap of 16 and PNG 
compression. The original WSI was tiled similarly to the confidence mask, except for using 
JPEG compression (quality 80). 
7. Slide-level classifier 
7.1. Model 
We employed a model-based approach relying on boosted trees, implemented using 
XGBoost16, for aggregating patch-level predictions into slide-level predictions (see Figure 
S2). We trained one boosted tree classifier based on the patch-level predictions of each 
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CNN, thus forming ensembles of boosted trees. We trained one ensemble for each slide-
level prediction task: 1) cancer detection (based on the first-stage CNN ensemble) and 2) 
estimation of cancer length (based on the first-stage CNN ensemble), and 3) Gleason 
grading (based on the second stage CNN ensemble). 
 
For a slide with n patches, we extracted slide-level features from the n x c matrix of class-
wise probabilities estimated by a CNN for c classes (c = 2 for the first stage CNNs, c = 4 for 
the second stage CNNs).  
 
The following features were computed for each slide in class-wise manner over all n 
patches, each resulting in a 1 x c vector: 
- Sum 
- Median 
- Maximum 
- 99.75th percentile 
- 99.50th percentile 
- 99.25th percentile 
- 99th percentile 
- 98th percentile 
- 95th percentile 
- 90th percentile 
- 80th percentile 
- 10th percentile 
- Number of patches with probability > 0.999 
- Number of patches with probability > 0.99 
- Number of patches with probability > 0.9 
 
The following features were additionally computed for each slide: 
- Total number of patches n (1x1) 
- Number of patches where each class had the highest probability (1 x c) 
7.2. Training 
For training ensembles of boosted trees for cancer detection and cancer length estimation, 
we used features (see Section 7.1.) computed from the predictions generated for all training 
slides by the 30 CNNs in the cancer detection ensemble. For cancer detection, we used the 
binary logistic (‘binary:logistic’) loss function, a maximum tree depth of 5, and 100 iterations. 
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For the cancer length estimation, we used the linear regression (‘reg:linear’) loss function, a 
maximum tree depth of 2, and 200 iterations. 
 
For training an ensemble of boosted trees for ISUP grading, we used features extracted from 
the predictions generated for all training slides by the 30 CNNs in the grading ensemble. We 
used the softmax (‘multi:softprob’) loss function, a maximum tree depth of 3, and 300 
iterations. To handle class imbalance, we applied sample weights, which were inversely 
proportional to the number of training samples representing each ISUP class. 
 
In order to select the maximum tree depth and the number of trees, which we considered the 
key parameters for the boosted tree models, we performed a parameter grid search. The 
grid search was evaluated on a 5-fold patient-level cross validation on the training data, with 
an ensemble of 5 cancer detection CNNs and 5 grading CNNs trained for each fold (see 
Section 8.4.; Figure S5-S7). For other parameters, we used the following (default) values: 
booster: gbtree; eta: 0.3; gamma: 0; min_child_weight: 1; max_delta_step: 0; subsample: 1; 
colsample_bytree: 1; colsample_bylevel: 1; lambda: 1; alpha: 0; tree_method: auto; 
sketch_eps: 0.03; scale_pos_weight: 1; updater: [grow_colmaker, prune]; refresh_leaf: 1; 
process_type: default; grow_policy: depthwise; max_leaves: 0; max_bin: 256; predictor: 
cpu_predictor. 
7.3. Prediction  
In the slide-level prediction phase, the patch-level predictions generated by the CNN 
ensembles (see Section 6.3.) were aggregated into slide-level features (see Section 7.1) and 
provided as input to the trained ensembles of boosted trees (see Section 7.2). 
 
Probability of cancer of any grade being present was computed for each slide as the mean 
of the probabilities output by the 30 boosted trees comprising the cancer detection 
ensemble. A final estimate of cancer length for each slide was obtained by computing the 
mean of the predictions generated by the 30 boosted trees in the length estimation 
ensemble. Any negative values were replaced by zero. Grade-specific probabilities of cancer 
were computed for each slide as the mean of the probabilities output by the 30 boosted trees 
comprising the grading ensemble. 
 
We obtained a final classification outcome for each slide by assigning the slide as benign if 
the average probability estimated by the cancer detection ensemble was below a chosen 
threshold corresponding to an operating point of choice. The grading results presented in 
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this study are based on an operating point corresponding to a sensitivity of 99%. For slides 
with probabilities exceeding the threshold and thus classified as malignant, the ISUP score 
was assigned based on a Bayesian decision rule. The aim of using this approach instead of 
a simple argmax-rule, based on the estimated probabilities alone, was to encourage 
assigning higher rather than lower ISUP scores and to recognize the varying severity of 
misclassifications on the ordinal ISUP scale. More specifically, we assigned the grade to 
each slide predicted as malignant such that: 
 
         (  |  ) 
 
that is, given the input class-wise probabilities x, we choose the grade a that minimizes the 
conditional risk: 
 (  |  )  =  
 
 (  |  )  ( ,  ) 
where L(y,a) defines the loss associated with assigning grade a when the true grade is y. 
We defined our loss matrix L such that: 
 
 
that is, underestimating a grade is perceived as twice as costly as overestimating a grade, 
and the cost increases linearly with the magnitude of the error. It should be noted, that this 
choice of preferring overestimation of ISUP score over underestimation by a factor of two is 
arbitrary. We based our decision on considerations of the clinical consequences of 
underestimation relative to overestimation, and on cross-validation experiments. 
8. Supplementary results 
8.1. Model architecture comparison 
We compared different CNN architectures in terms of their performance based on a single 
validation split, where a random selection of 20% and 80% of the men in training data were 
allocated for validation and training, respectively (i.e. no data from the test set was used for 
these experiments). In contrast to the data used for subsequent cross validation experiments 
and final model training, the dataset used in this experiment did not yet include the additional 
set of 271 slides from 93 men with high grade disease collected outside the Stockholm-3 
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trial. Therefore, for the purposes of this experiment, we pooled together all patches 
representing an ISUP score of 5. That is, malignant patches from slides with a Gleason 
score of 4+5, 5+4 or 5+5 were all used as examples of Gleason pattern 5 in training. 
 
We included the following architectures in the comparison: Inception V38, ResNet509, 
Inception-ResNet V210 and Xception11. For each architecture, we trained an ensemble of 5 
CNNs for various numbers of epochs (see Section 6 for details). In this experiment, we used 
a single CNN ensemble for cancer detection, cancer length estimation and grading. For each 
architecture and number of epochs, we then trained three ensembles of boosted trees for 
cancer detection, cancer length estimation and grading, using the patch-level predictions 
from training slides as input (see Section 7 for details). 
 
We evaluated the performance of each CNN architecture in: 1) cancer detection based on 
the AUC of discriminating malignant from benign biopsies, 2) cancer length estimation based 
on the linear correlation coefficient between estimated and reported lengths, and 3) grading 
based on Cohen’s kappa computed between the ISUP grades assigned by the AI and the 
study pathologist for biopsies indicated as malignant by the pathologist (Table S2). The 
results indicated that out of the evaluated architectures, Inception V3 achieved the best 
performance in all three tasks. 
8.2. Model ensembling 
We evaluated the value of ensembling multiple CNNs to improve generalization based on a 
5-fold patient-level cross validation on training data. For each fold, we used patches from the 
slides of the training patients in that fold to train an ensemble of 5 Inception V3 models for 
cancer detection and length estimation (see Section 6 for details). We trained all models for 
15 epochs. For each fold, we then trained two ensembles of boosted trees for cancer 
detection and cancer length estimation, using the patch-level predictions generated by 1-5 
CNNs for training slides as input (see Section 7 for details).  
 
The trained patch- and slide-level ensembles were then applied to generate predictions for 
the validation slides in each fold, and the results were aggregated over all five folds. We 
evaluated performance as a function of ensemble size in cancer detection based on the 
AUC of discriminating malignant from benign biopsies, and in cancer length estimation 
based on the linear correlation coefficient between estimated and reported lengths (see 
Table S3). We observed a trend of increasing AUC and correlation with increasing ensemble 
size. 
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8.3. Number of epochs 
We evaluated the optimal number of training epochs for the first stage ensemble of cancer 
detection CNNs and the second stage ensemble of cancer grading CNNs, based on a 5-fold 
patient-level cross validation on training data. For each fold, we used patches from the slides 
of the training patients in that fold to train two ensembles, each consisting of 5 Inception V3 
models (see Section 6 for details). We then trained three ensembles of boosted trees for 
cancer detection, cancer length estimation and grading, using the patch-level predictions 
from training slides as input (see Section 7 for details). The trained patch- and slide-level 
ensembles were then applied to generate predictions for the validation slides in each fold, 
and the results were aggregated over all five folds. The entire process was repeated using 
either 10, 15 or 20 epochs for training the first stage ensemble, and either 40, 60 or 80 
epochs for training the second stage ensemble. 
 
One should note that the amount and class distribution of available training data is different 
for the two stages, which means that the epoch numbers are not comparable between the 
two ensembles. It is also worth pointing out, that our sampling over the number of epochs is 
very sparse compared to usual CNN training curves, where training and validation accuracy 
are typically presented for every epoch. The reason for this is that evaluating the 
performance of our system at the slide level requires: 1) applying all trained CNNs 
comprising the two ensembles to generate predictions for all tissue patches in the training 
slides, 2) training an ensemble of boosted trees, and 3) applying both the CNN ensembles 
and the boosted tree ensembles to generate predictions for validation slides. The 
computational cost of repeating this process after every epoch in a cross-validation setting 
would have been prohibitively high. An alternative would have been to assess training 
curves based on patch-level metrics computed on a limited set of validation patches. 
However, based on our observations, drawing conclusions on slide level performance based 
only on patch-level metrics is not straightforward, mainly due to the considerable amount of 
noise associated with our pixel-level and patch-level ground truth annotations. We therefore 
chose to evaluate the performance of the system with a sparse sampling over epochs, but 
with a focus on the slide-level metrics, which are easy to interpret and relevant in view of the 
system’s potential clinical utility. 
 
We evaluated the effect of the number of epochs on: 1) cancer detection based on the AUC 
of discriminating malignant from benign biopsies (Table S4), 2) cancer length estimation 
based on the linear correlation coefficient between estimated and reported lengths (Table 
S4), and 3) grading based on Cohen’s kappa computed between the ISUP grades assigned 
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by the AI and the study pathologist for biopsies indicated as malignant by the pathologist 
(Table S5). Based on these results, we selected 15 and 60 as the optimal number of epochs 
for the first and the second stage CNN ensembles, respectively. 
8.4. Boosted tree hyperparameter selection 
To select hyperparameter values for boosted trees, we performed a grid search over 
different tree numbers and tree depths (see Section 7) and evaluated them on a 5-fold 
patient-level cross validation on training data. More specifically, we used the patches from 
slides corresponding to the training patients of each fold to train an ensemble of 5 Inception 
V3 models for cancer detection and cancer length estimation, and an ensemble of 5 
Inception V3 models for grading (see Section 6 for details). That is, we trained a total of 50 
CNNs for this experiment. The cancer detection models were trained for 15 epochs and the 
grading models for 60 epochs. 
 
For each fold, we then trained three ensembles of boosted trees for cancer detection, cancer 
length estimation and grading, using the patch-level predictions from training slides as input 
(see Section 7 for details). The training of these boosted trees was repeated with different 
combinations of tree depths (2-5), and number of trees (20-400). The trained patch- and 
slide-level ensembles were then applied to generate predictions for the validation slides in 
each fold, and the results were aggregated over all five folds. We thus obtained a set of 
predictions for all slides in our training data, based on different tree depth and tree number 
values.  
 
We evaluated the effects of these parameter choices on: 1) cancer detection based on the 
AUC of discriminating malignant from benign biopsies (Figure S5), 2) cancer length 
estimation based on the linear correlation coefficient between estimated and reported 
lengths (Figure S6), and 3) grading based on Cohen’s kappa computed between the ISUP 
grades assigned by the AI and the study pathologist for biopsies indicated as malignant by 
the pathologist (Figure S7). For each of the three tasks, we chose parameter values 
corresponding to relatively stable regions of high AUC, correlation and Cohen’s kappa, 
respectively, to be used for the final model training. 
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9. Supplementary Figures 
 
 
Figure S1: Image pre-processing workflow. (A) From left to right: tissue (blue outline) and 
annotations drawn with a pen (red outline) are segmented from the input WSI and stored as binary 
masks. The annotations are then digitized by projecting the pen marks onto adjacent tissue, and the 
result is stored as a label mask indicating benign (grey), cancerous (white) and unknown or 
background (black) pixels. The unknown label is assigned to non-annotated tissue sections on 
cancerous slides, such as the one here on the left, and pixels adjacent to cancerous tissue within a 
specified margin. (B) Each WSI is tiled into partially overlapping image patches, extracted from the 
regions indicated in the tissue mask, resulting in approximately 1000 patches per WSI. In the process, 
non-tissue pixels are assigned a constant white value to remove any background and pen mark 
patterns. Each patch is then assigned a label based on the label mask, and benign and cancerous 
patches are subsequently used as training data. Patches with the unknown label are only used as 
input in the prediction phase. 
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Figure S2: Overview of the artificial intelligence system. The tissue region in the input WSI is split 
into patches (top). The patches are fed as input to a detection ensemble of 30 DNNs for 
discriminating between benign and malignant patches (left box; top row), and to a grading ensemble 
of 30 DNNs for classifying patches into Gleason grades 3, 4 and 5 (right box; top row). In the patch-
level prediction phase (both boxes; middle row), each trained DNN outputs a vector of class-wise 
probabilities for each input patch. The class-wise probabilities, indicated here with squares where the 
grayscale intensity corresponds to probability value, are mapped back to the locations of the 
corresponding patches in the WSI to construct a probability map for each class. The maps are 
summarized into features, which are used as inputs to train ensembles of boosted trees to predict 
cancer presence and extent (left box; bottom row) and grade (right box; bottom row) for entire 
WSIs. In the WSI-level prediction phase, outputs from the 30 boosted trees in each ensemble are 
averaged, and the final classification of each WSI is assigned to the class associated with the highest 
average probability. 
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Figure S3: Grading performance relative to ISUP expert panel on Imagebase. The distribution of 
ISUP scores given by the 23 pathologists from the ISUP expert panel and the AI for each of the 87 
case IDs in Imagebase. Each row corresponds to one case, and the cases are organized into three 
plots according to average ISUP score increasing from left to right, and from top to bottom. The areas 
of the blue circles represent the proportion of pathologists who voted for a specific ISUP score (x-
axis). The red dot indicates the ISUP score given by the AI. Example: in the last row (bottom-right; 
case ID 5) most pathologists voted ISUP 5 and a minority voted ISUP 4; the red dot indicates that the 
AI voted ISUP 4. 
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Figure S4: Grading performance on independent test data. A confusion matrix on the independent 
test data of 1631 slides. The pathologist’s (L.E.) grading is shown on the y-axis and the AI’s grading 
on the x-axis. Cohen’s kappa with linear weights was 0.83 when considering all cases, and 0.70 when 
only considering the cases indicated as positive by the pathologist. 
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Figure S5: Effect of boosted tree parameters on cancer detection. The AUC for discriminating 
between benign and malignant biopsies is shown for different numbers of trees and tree depths, 
estimated using cross-validation on the training data. 
  
 40 
 
 
Figure S6: Effect of boosted tree parameters on cancer length estimation. The linear correlation 
coefficient between estimated cancer length and that reported by the study pathologist for each 
biopsy is shown for different numbers of trees and tree depths, estimated using cross-validation on 
the training data. 
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Figure S7: Effect of boosted tree parameters on cancer grading. Cohen’s kappa between 
estimated ISUP scores and those reported by the study pathologist for all malignant biopsies is shown 
for different numbers of trees and tree depths, estimated using cross-validation on the training data. 
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10. Supplementary Tables 
Table S1: Data management workflow and quality control. Scanned slides were linked back to 
clinical data. We excluded slides with corrupted filenames, slides that did not pass the visual quality 
control, slides that were duplicated during scanning and slides that were not consistent with clinical 
data. 
 N 
Total scanned slides 10185 
Excluded slides  
Non-matching ID filename and clinical data 268 
Rescanned slide 613 
Quality control (IHC, failed staining, corrupted data) 120 
Duplicates scanning 45 
Clinical data and penmark non-matching 297 
Total remaining slides 8842 
 
 
Table S2: Comparison of CNN architectures. Cancer detection (AUC), cancer length estimation 
(Correlation) and grading (Cohen’s kappa) performance of ensembles representing different CNN 
architectures, estimated using cross-validation on the training data. The highest value for each metric 
is highlighted in bold italic. 
Architecture (epochs) AUC Correlation Cohen’s kappa 
Inception V3 (20) 0.984 0.943 0.64 
Inception V3 (30) 0.987 0.939 0.63 
Inception V3 (40) 0.984 0.935 0.62 
ResNet-50 (20) 0.983 0.933 0.57 
ResNet-50 (30) 0.980 0.935 0.60 
ResNet-50 (40) 0.982 0.932 0.55 
Inception-ResNet V2 (20) 0.983 0.939 0.61 
Inception-ResNet V2 (30) 0.984 0.939 0.62 
Xception (20) 0.985 0.937 0.58 
Xception (30) 0.985 0.939 0.58 
 
 
Table S3: Effect of ensemble size on cancer detection and length estimation performance. 
Cancer detection (AUC) and length estimation (Correlation) performance as a function of ensemble 
size for 1-5 Inception V3 models, estimated using cross-validation on the training data.  
 n = 1 n = 2 n = 3 n = 4 n = 5 
AUC 0.988 0.991 0.991 0.992 0.993 
Correlation 0.946 0.941 0.948 0.949 0.949 
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Table S4: Effect of training epochs on cancer detection and length estimation performance. 
Cancer detection (AUC) and length estimation (Correlation) performance as a function of training 
epochs for an ensemble of 5 Inception V3 models, estimated using cross-validation on the training 
data. 
 10 epochs 15 epochs 20 epochs 
AUC 0.991 0.993 0.992 
Correlation 0.947 0.949 0.948 
 
 
Table S5: Effect of training epochs on cancer grading performance. Cancer grading performance 
(Cohen’s kappa) as a function of training epochs for an ensemble of 5 Inception V3 models, estimated 
using cross-validation on the training data. 
 40 epochs 60 epochs 80 epochs 
Cohen’s kappa 0.66 0.67 0.66 
 
 
Table S6: Prevalence of different complementary findings. The number of various histological 
variants tabulated for the full STHLM3 dataset as well as the training and testing sets used in this 
study. * Cancer of pseudohyperplastic or atrophic type. § Not including extended training data from 
StGöran Hospital. 
Complementary findings 
All STHLM3 biopsy cores 
(n=83,470) 
 
No. (%) 
Training data 
cores (n=6,682) § 
 
No. (%) 
Test data 
cores 
(n=1,631) 
 
No. (%) 
Atypia of unknown significance or suspicious for 
cancer 
   
No 82762 (99.2) 6671 (99.8) 1627 (99.8) 
Yes 708 (0.9) 11 (0.2) 4 (0.2) 
Prostatic Intraepithelial Neoplasia (PIN) 
   
No 83424 (99.9) 6681 (100.0) 1630 (99.9) 
Yes 46 (0.1) 1 (0.0) 1 (0.1) 
Deceptively bland variants of acinar 
adenocarcinoma* 
   
No 83421 (99.9) 6677 (99.9) 1627 (99.8) 
Yes 49 (0.1) 5 (0.1) 4 (0.2) 
Adenosis 
   
No 83458 (100.0) 6682 (100.0) 1631 (100.0) 
Yes 12 (0.0) 0 (0.0) 0 (0.0) 
Immunohistochemistry performed 
   
No 82644 (99.0) 6569 (98.3) 1601 (98.2) 
Yes 826 (1.0) 113 (1.7) 30 (1.8) 
 44 
 
Supplementary references 
1 Goode A, Gilbert B, Harkes J, Jukic D. OpenSlide: A vendor-neutral software 
foundation for digital pathology. J Pathol 2013. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815078/. 
2 Forsberg D. openslide-matlab. Github https://github.com/fordanic/openslide-matlab 
(accessed Aug 30, 2018). 
3 Chollet F. Keras. 2015. 
4 Martín Abadi, Ashish Agarwal, Paul Barham, et al. TensorFlow: Large-Scale Machine 
Learning on Heterogeneous Systems. 2015. https://www.tensorflow.org/. 
5 Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst 
Man Cybern 1979; 9: 62–6. 
6 Friedman JH, Bentley JL, Finkel RA. An Algorithm for Finding Best Matches in 
Logarithmic Expected Time. ACM Trans Math Softw 1977; 3: 209–26. 
7 Berens P, Others. CircStat: a MATLAB toolbox for circular statistics. J Stat Softw 
2009; 31: 1–21. 
8 Szegedy C, Vanhoucke V, Ioffe S, Shlens J, Wojna Z. Rethinking the inception 
architecture for computer vision. In: Proceedings of the IEEE conference on computer 
vision and pattern recognition. 2016: 2818–26. 
9 He K, Zhang X, Ren S, Sun J. Deep residual learning for image recognition. In: 
Proceedings of the IEEE conference on computer vision and pattern recognition. 
2016: 770–8. 
10 Szegedy C, Ioffe S, Vanhoucke V, Alemi AA. Inception-v4, inception-resnet and the 
impact of residual connections on learning. In: AAAI. 2017: 12. 
11 Chollet F. Xception: Deep Learning with Depthwise Separable Convolutions. In: 2017 
IEEE Conference on Computer Vision and Pattern Recognition (CVPR). 2017: 1800–
7. 
12 Buda M, Maki A, Mazurowski MA. A systematic study of the class imbalance problem 
in convolutional neural networks. Neural Netw 2018; 106: 249–59. 
13 Kinga D, Adam JB. A method for stochastic optimization. In: International Conference 
on Learning Representations (ICLR). 2015. 
14 Russakovsky O, Deng J, Su H, et al. ImageNet Large Scale Visual Recognition 
Challenge. Int J Comput Vis 2015; 115: 211–52. 
15 Martinez K, Cupitt J. VIPS - a highly tuned image processing software architecture. In: 
IEEE International Conference on Image Processing 2005. 2005. 
DOI:10.1109/icip.2005.1530120. 
16 Chen T, Guestrin C. XGBoost. Proceedings of the 22nd ACM SIGKDD International 
 45 
 
Conference on Knowledge Discovery and Data Mining - KDD ’16. 2016. 
DOI:10.1145/2939672.2939785. 
 
 
 
 
